BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
Macquarie initiates Cadila Healthcare with outperform
Targets implies upside potential of 25 per cent. Large niche US pipeline augurs well for growth.See potential for US business to double in 3 years.
US business is key lever driving EBITDA margin expansion.